604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

✍ Scribed by Awada, A.; Delord, J.P.; Houédé, N.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; Rottey, S.; Kefford, R.; Rejeb, N.; Raymond, E.

• Book ID: 121971167
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 78 KB
• Volume: 48
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/S0959-8049(12)72401-2